Long COVID's hiding place may be your gut, not your blood

Key Findings

💊 Two Repurposed Drugs, One Honest Result

• A randomized trial published in Annals of Internal Medicine tested fluvoxamine (an antidepressant) and metformin (a diabetes drug) for long COVID fatigue.
• Fatigue is one of the most common and debilitating long COVID symptoms — and neither drug has an obvious biological reason to fix it, which is exactly why repurposing trials like this matter.

🧠 Brain Fog Is Its Own Thing — Not Just Tired Thinking

• A cognitive study of over 24,000 people, including 548 with long COVID, found that persistent symptoms were linked to deficits in sustained attention — independent of fatigue.
• Path modeling showed long COVID affects attention and memory through two routes simultaneously: direct neural effects and fatigue-driven performance drag. That hybrid pattern is distinct from aging and most mental health disorders.

🧲 A Magnetic Helmet for Brain Fog Gets Its First Trial

• A small pilot randomized 30 long COVID patients 2:1 to active or sham microtesla magnetic therapy — a low-amplitude radiofrequency field delivered via a head-worn device twice weekly for 4 weeks.
• Active treatment was associated with larger improvements on three cognitive measures at 8 weeks, including verbal recall and digit sequencing. All 30 who completed the study hit 100% treatment adherence. No device-related adverse events occurred.

💸 Long COVID Costs About $80K Per Patient Over Three Years

• A Colorado claims database study tracked 25,229 long COVID patients and 126,089 comparison patients across commercial, Medicare, Medicaid, and dual coverage.
• Long COVID patients averaged $79,777 in total expenditures over three years, with $5,158 in out-of-pocket cost-sharing. Spending spiked about six months before diagnosis and returned to baseline within six months after — but excess spending totaled $21,597 per patient.

🏃 Exercise for Long COVID Fatigue: A Systematic Review Weighs In

• Fatigue is one of long COVID's most reported and disabling symptoms — often accompanied by reduced activity tolerance and shortness of breath on exertion.
• A new systematic review and meta-analysis synthesized the available evidence on exercise as an intervention, offering the first comprehensive look at what the trial data actually shows across studies.

🩸 When the Problem Isn't Just Inside the Blood Vessels

• A theoretical framework paper proposes that long COVID's vascular damage doesn't stop at the vessel wall — fibrin may leak into surrounding tissue and fail to fully resolve, creating what the authors call a dual-axis problem: impaired blood supply plus abnormal interstitial mechanics.
• The model generates testable predictions for histological, imaging, and biomechanical studies and links established microvascular findings to an underexplored extravascular component.